-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venglustat Malate in Sandhoff Disease (Jatzkewitz-Pilz Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venglustat Malate in Sandhoff Disease (Jatzkewitz-Pilz Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Venglustat Malate in Sandhoff Disease (Jatzkewitz-Pilz Syndrome)Drug Details: Venglustat malate...
-
Product Insights
Bone Growth Stimulators Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Bone Growth Stimulators Pipeline Market Report Overview Bone growth stimulators are mainly used to facilitate bone growth in impaired or delayed healing fractures or fusions. They apply electrical or ultrasound waves to the site of the fracture or fusion. The bone growth stimulators pipeline market research report provides comprehensive information about the bone growth stimulators pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key...
-
Company Profile
First Wave BioPharma Inc – Company Profile
First Wave BioPharma Inc (First Wave BioPharma), formerly AzurRx BioPharma Inc, is a development-stage biopharmaceutical company that focuses on non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company's products under development include MS1819 a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). MS1819 completed the phase IIa trial in partnership with Mayoly which is a European Pharmaceutical company. Its pre-clinical products...
Add to Basket -
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...
-
Product Insights
Net Present Value Model: Adrulipase alfa
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Adrulipase alfa Drug Details Adrulipase alfa...
-
Product Insights
Net Present Value Model: FW-1022
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model FW-1022 Drug Details Niclosamide is under...
-
Product Insights
Net Present Value Model: Niclosamide
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Niclosamide Drug Details Niclosamide is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – niclosamide
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry niclosamide Drug Details Niclosamide is under development for the treatment of metastatic hormone-refractory (castration-resistant,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – niclosamide
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry niclosamide Drug Details Niclosamide (ATx-201) is under development for the treatment of atopic dermatitis, ...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – adrulipase alfa
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry adrulipase alfa Drug Details Adrulipase alfa is under development for the treatment of exocrine...